STAAR Surgical(NASDAQ) STAA

STAAR Surgical Company makes tiny lenses for the human eye. These lenses help people see better without glasses or contacts. Doctors put them inside the eye to fix blurry vision.

Better Vision Without Glasses

• Implantable Collamer Lenses: Flexible lenses made from a proprietary biocompatible material for vision correction; accounted for nearly all net sales in the three-month period ended July 3, 2026.
• EVO and EVO+: Specific lens models designed to be inserted through small incisions during minimally invasive refractive surgery to improve light focus.
• Intraocular Lenses: Preloaded silicone lenses and injector systems used by surgeons to replace cloudy natural lenses during cataract surgery.
• Delivery Systems: Professional injector components and ancillary medical instruments used to safely place corrective lenses into the eye.

Strategic Moves and Changes

• Opened a new manufacturing facility in Switzerland to scale the production of EVO lenses for the Chinese market.
• Ended a planned merger with Alcon in Jan. 2026 after a shareholder vote against the transaction.
• Entered a cooperation agreement in 2026 with investment firms Broadwood, Yunqi Capital, and Defender Capital following the terminated merger.
• Launched an enterprise resource planning system during the second quarter of 2026 to manage growing global sales volumes.

The Secret Is the Material

The company uses a proprietary material called Collamer that is biocompatible with the human eye. It reaches customers through a direct sales force in major markets and independent distributors in other global regions.

Performance by the Numbers

• Net sales reached $93.5 million in the three-month period ended July 3, 2026, up 111.0% year over year.
• Gross profit margin rose to 74.5% in the second quarter of 2026 from 74.0% in the prior-year period.
• GAAP net income was $8.1 million for the three-month period ended July 3, 2026, compared to a net loss of $16.8 million in the previous year.
• Cash and investments available for sale totaled $181.5 million as of July 3, 2026.
• Sales in the Asia Pacific region increased 189% in the three-month period ended July 3, 2026, driven by growth in China and Japan.

Bottom Line

STAAR Surgical has evolved from a broad ophthalmic tool maker into a specialized leader in implantable refractive lenses. Its focus on proprietary materials and expansion in Asian markets drives its current business model.